TNFSF10 and melanoma: We confirmed the hypertonicity-granted boost in TRAIL cytotoxicity in other cell lines established from malignant melanoma (IGR-1 and A2058, Supplementary Figure S1b and c), colorectal cancer (HCT116, Fig. 1e,f and HT-29, Supplementary Figure S1d), acute lymphoblastic leukemia (REH), oral squamous cell carcinoma (PCI-68, Supplementary Figure S1e and f), and spheroid cultures (HCT116 spheroids, Supplementary Figure S1g) cells to exclude cell line-, tumor entity- or cell culture technique-specific phenomena.